Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Kidney cancer

First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC

Nature Reviews Clinical Oncology volume 20, page 661 (2023)Cite this article

Subjects

Although 25% of patients with renal cell carcinoma (RCC) have a non-clear-cell histology, this population has typically not been included in pivotal phase III trials in advanced-stage disease. As a result, optimal treatment options for these patients are not well established. Now, results from the single-arm phase II KEYNOTE-B61 trial, involving only patients with advanced-stage non-clear-cell RCC, show durable responses with first-line pembrolizumab plus lenvatinib.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    Diana Romero

Authors
  1. Diana Romero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Diana Romero.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Romero, D. First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC. Nat Rev Clin Oncol 20, 661 (2023). https://doi.org/10.1038/s41571-023-00809-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-023-00809-3

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing